BRISBANE, Australia and CARLSBAD, Calif., Aug. 10, 2016 /PRNewswire/ -- ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announced that Scripps Health will use the SOZOTM device in a validation study for monitoring patients with heart failure who are currently being tracked using pulmonary artery pressure monitoring. The validation study will provide real-world data necessary for the final design of the pivotal trial.
The study is being led by J. Thomas Heywood, MD, Director, Heart Failure Recovery and Research Program, and Andrew Accardi, MD, Chairman of Emergency Medicine. Both physicians are members of Scripps Health and ImpediMed's Medical Advisory Board. Dr. Heywood's patients at Scripps Green Hospital, part of the Scripps Health system, will be recruited for the study.